Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralinepag Open-Label Extension in PAH
NCT02279745Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Jul 2015; status: completed.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02279745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279745.